Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
Abstract Background Idarucizumab, a monoclonal antibody fragment that reverses the anticoagulant effect of dabigatran, was approved for use in Canada in 2016. Objective Our objective was to assess the safety of idarucizumab among patients who received the drug within the first 3 years of its use in...
Gorde:
| Egile Nagusiak: | , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Elsevier
2021-07-01
|
| Saila: | Research and Practice in Thrombosis and Haemostasis |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1002/rth2.12535 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|